Last verified 2026-08-15

Zepbound for sleep apnea: what coverage actually looks like

There is now a drug approved to treat obstructive sleep apnea. That’s genuinely new — for decades the options were a machine, an appliance, or surgery.

Whether you can get it is a separate question from whether it works, and for most people the second question is the harder one.

What was approved, and for whom

The FDA approved tirzepatide — sold as Zepbound — for moderate-to-severe obstructive sleep apnea in adults with obesity. It remains the only medication with an FDA approval specifically for OSA.

Read that indication carefully, because it’s narrower than the headlines suggested and it’s the sentence your insurer will be reading too. Three conditions: moderate-to-severe OSA, confirmed by a sleep study. Adult. And obesity.

It is not approved for mild OSA. It is not approved for central sleep apnea. And it is not approved for OSA in someone who doesn’t meet the weight criterion, however much they might want it.

What the trials actually showed

The evidence comes from two phase 3 trials, published in the New England Journal of Medicine. Participants had moderate-to-severe OSA and obesity. One trial studied people not using PAP therapy; the other studied people already on PAP, whose therapy was withdrawn before measurement.

The results were substantial. In the trial of PAP users, average AHI fell by about 29 events per hour after a year, against about 5 events per hour on placebo — a treatment difference of roughly 24 events per hour. Across the program, the manufacturer reported mean AHI reductions of up to about 63%, and up to roughly half of participants met the trials’ predefined criteria for disease resolution.

Now the parts that get left out.

Roughly half of participants did not reach that resolution threshold. “Up to 51.5%” is a real and impressive number, and it also means that for about half, the condition was improved but not resolved. If you start at an AHI of 50 and drop 29 events, you have made an enormous improvement and you still have moderate sleep apnea.

“Disease resolution” was a trial definition, based on specified AHI and sleepiness-scale thresholds — not a doctor telling you that you no longer have sleep apnea. Anyone stopping therapy on that basis needs a repeat sleep study, not an assumption.

It was studied for 52 weeks. This is a weekly injection that works substantially through weight reduction. What happens to AHI if the medication stops was not what these trials were designed to answer, and the honest expectation is that the condition tracks the weight.

The most common side effects were gastrointestinal, generally mild to moderate — the same profile seen across this drug class.

None of that makes it a weak result. It’s the most significant new option in sleep apnea treatment in a long time. It is also not a cure, and the gap between those two statements is where most coverage of this drug lives.

Medicare

Medicare Part D can cover Zepbound when it’s prescribed for obstructive sleep apnea in someone with obesity. It does not cover it — or any GLP-1 — for weight loss alone. CMS considered broadening anti-obesity drug coverage for 2026 and ultimately decided against it, which means the sleep apnea indication remains the pathway.

Practically, that requires: enrollment in a Part D plan, whether standalone or through Medicare Advantage; a documented OSA diagnosis confirmed by a sleep study or home sleep apnea test; and in most cases prior authorization.

On cost, two things changed recently. Part D now carries an annual out-of-pocket cap for covered drugs. And under an agreement between the manufacturer and the federal government, eligible Medicare beneficiaries began paying roughly $50 per month from April 2026, against a fixed Medicare price of around $245.

If you were quoted a Medicare price before 2026, it’s worth asking again.

Commercial insurance

This is where it gets unpredictable, and where the honest answer is that your plan’s decision has more to do with your employer’s pharmacy benefit design than with your diagnosis.

Coverage generally requires the drug to be on your plan’s formulary at all, prior authorization approved, and the correct documentation submitted with the initial request. Approvals are often issued for a defined period — six months is common — after which continuation has to be justified.

Formulary placement has been volatile. One of the largest pharmacy benefit managers removed Zepbound from its formulary in 2025, and multiple class-action suits have been filed challenging the resulting denials. Patients have received non-coverage notices at plan renewal for a drug their plan covered the year before.

The practical implication: check your plan’s current formulary before you fill anything, not before you’re prescribed it. Coverage that existed in January may not exist in the next plan year.

What prior authorization typically asks for

Requirements vary by payer, but the pattern across published policies is consistent:

• The prescription is for obstructive sleep apnea, not weight management
• A diagnosis confirmed by polysomnography or a home sleep apnea test, with the AHI documented
• Documentation that the OSA is moderate-to-severe
• Body mass index meeting the plan’s threshold
• Sometimes, documentation regarding PAP therapy — whether you’ve tried it, tolerate it, or are using it concurrently

That last one matters. Some plans want to see PAP attempted first. Some accept concurrent use. Some treat the drug as an add-on rather than a replacement. Your prescriber needs to know which framing your specific plan expects before submitting, because a request framed wrongly gets denied on its merits rather than on the facts.

If you’re denied, appeal. The FDA indication for OSA is the strongest argument available, and a denial on the grounds that this is a weight-loss drug is answerable with the label itself.

Without coverage

List price is roughly $1,000 per month. With coverage, most people pay something between $25 and $150 depending on plan and tier.

Manufacturer savings programs and direct-purchase options exist and change frequently enough that any figure printed here would be stale. Check the manufacturer’s current program directly rather than relying on a third-party summary, this page included.

Where this fits

The framing that gets lost: this was studied alongside PAP therapy, not only against it. One of the two trials specifically enrolled people already using PAP.

For some people the drug may reduce OSA enough that PAP is no longer indicated — that’s what the resolution endpoint was measuring. For many others it will meaningfully reduce severity while PAP or an oral appliance continues to do the rest. Both are legitimate outcomes.

What it should not be is a reason to stop existing therapy on your own. The trials withdrew PAP under controlled conditions with a sleep study to measure the result. Stopping at home without one means neither you nor your clinician knows what your AHI is now.

If it works well for you, the conversation to have is: should I repeat the sleep study to see where I actually am? That’s a question with an answer. Guessing isn’t.

Coverage rules for this medication are changing quickly. The details above were verified on the date shown and are worth re-checking against your own plan’s current formulary before making any decision. This page describes how the drug is approved and covered in the United States; it is not medical advice, and whether it’s appropriate for you is a question for the clinician managing your care.